Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists
Ulrich R. Hengge, Thomas Ruzicka
Dermatologic Surgery (2004) Vol. 30, Iss. 8, pp. 1101-1112
Closed Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Imiquimod: mode of action
Michael P. Schön, Michael P. Schön
British Journal of Dermatology (2007) Vol. 157, pp. 8-13
Closed Access | Times Cited: 322
TLR7 and TLR8 as targets in cancer therapy
Michael P. Schön, Michael P. Schön
Oncogene (2008) Vol. 27, Iss. 2, pp. 190-199
Closed Access | Times Cited: 283
Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling
Behnam Kalali, Gabriele Köllisch, Jörg Mages, et al.
The Journal of Immunology (2008) Vol. 181, Iss. 4, pp. 2694-2704
Open Access | Times Cited: 176
Therapy for genital human papillomavirus-related disease
Charles Lacey
Journal of Clinical Virology (2005) Vol. 32, pp. 82-90
Closed Access | Times Cited: 175
Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients
Claas Ulrich, Jens Bichel, Sylvie Euvrard, et al.
British Journal of Dermatology (2007) Vol. 157, pp. 25-31
Open Access | Times Cited: 154
Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles
Ana Bocanegra, Ane Ruiz‐de‐Angulo, Aintzane Zabaleta, et al.
Biomaterials (2018) Vol. 170, pp. 95-115
Open Access | Times Cited: 93
Imiquimod Treatment of Anal Intraepithelial Neoplasia in HIV-Positive Men
Ulrike Wieland
Archives of Dermatology (2006) Vol. 142, Iss. 11, pp. 1438-1438
Closed Access | Times Cited: 134
Basal Cell Carcinoma with Mixed Histology: A Possible Pathogenesis for Recurrent Skin Cancer
Philip R Cohen, Keith E. Schulze, Bruce R. Nelson
Dermatologic Surgery (2006) Vol. 32, Iss. 4, pp. 542-551
Closed Access | Times Cited: 114
Immune response modifiers – mode of action
Meinhard Schiller, Dieter Metze, Thomas A. Luger, et al.
Experimental Dermatology (2006) Vol. 15, Iss. 5, pp. 331-341
Open Access | Times Cited: 113
Immunogenic anti-cancer chemotherapy as an emerging concept
Nicole M. Haynes, Robbert van der Most, Richard Lake, et al.
Current Opinion in Immunology (2008) Vol. 20, Iss. 5, pp. 545-557
Closed Access | Times Cited: 100
Treatment of Extramammary Paget Disease with Topical Imiquimod Cream: Case Report and Literature Review
Philip R. Cohen, Keith E. Schulze, Jaime A. Tschen, et al.
Southern Medical Journal (2006) Vol. 99, Iss. 4, pp. 396-402
Closed Access | Times Cited: 95
Tackling cutaneous herpes simplex virus disease with topical immunomodulators—a call to action
Luisa F. Duarte, Javier Carbone-Schellman, Susan M. Bueno, et al.
Clinical Microbiology Reviews (2025)
Closed Access
Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory
Chie Kohchi, Hiroyuki Inagawa, Takashi Nishizawa, et al.
Journal of Bioscience and Bioengineering (2006) Vol. 102, Iss. 6, pp. 485-496
Closed Access | Times Cited: 74
Imiquimod-loaded nanocapsules improve cytotoxicity in cervical cancer cell line
Luíza Abrahão Frank, Rafaela P. Gazzi, Paola de Andrade Mello, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2019) Vol. 136, pp. 9-17
Closed Access | Times Cited: 37
CpG Oligodeoxynucleotides Protect Newborn Mice from a Lethal Challenge with the Neurotropic Tacaribe Arenavirus
João Pedras-Vasconcelos, David Goucher, Montserrat Puig, et al.
The Journal of Immunology (2006) Vol. 176, Iss. 8, pp. 4940-4949
Open Access | Times Cited: 65
New pectin-based hydrogel containing imiquimod-loaded polymeric nanocapsules for melanoma treatment
Rafaela P. Gazzi, Luíza Abrahão Frank, Giovana R. Onzi, et al.
Drug Delivery and Translational Research (2020) Vol. 10, Iss. 6, pp. 1829-1840
Closed Access | Times Cited: 29
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine
Dean Johnston, Jean‐Claude Bystryn
Vaccine (2005) Vol. 24, Iss. 11, pp. 1958-1965
Closed Access | Times Cited: 58
Therapeutic targeting of pattern-recognition receptors
Nima Rezaei
International Immunopharmacology (2006) Vol. 6, Iss. 6, pp. 863-869
Closed Access | Times Cited: 55
The Use of Imiquimod in the Treatment of Periocular Tumours
Adam H. Ross, Claire Kennedy, C Collins, et al.
Orbit (2010) Vol. 29, Iss. 2, pp. 83-87
Closed Access | Times Cited: 41
Nanoparticle‐based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines
Peijie Zhou, Wei Liu, Yongsheng Cheng, et al.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2021) Vol. 13, Iss. 5
Open Access | Times Cited: 21
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Dean Johnston, Bushra Zaidi, Jean‐Claude Bystryn
Cancer Immunology Immunotherapy (2006) Vol. 56, Iss. 8, pp. 1133-1141
Open Access | Times Cited: 43
The Role of Topical Immune Response Modifiers in Skin Cancer
Courtney Woodmansee, Jessica Pillow, Robert B. Skinner
Drugs (2006) Vol. 66, Iss. 13, pp. 1657-1664
Closed Access | Times Cited: 43
Expression of Toll-Like Receptors in Verruca and Molluscum Contagiosum
Ja Kyung Ku, Hyun Jo Kwon, Mi‐Yeon Kim, et al.
Journal of Korean Medical Science (2008) Vol. 23, Iss. 2, pp. 307-307
Open Access | Times Cited: 41
Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer
Evangelia Papadavid, Alexandros Stratigos, Matthew E. Falagas
Expert Opinion on Pharmacotherapy (2007) Vol. 8, Iss. 11, pp. 1743-1755
Closed Access | Times Cited: 41
Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells
Cindy Grandjenette, Anne Kennel, G Fauré, et al.
Haematologica (2007) Vol. 92, Iss. 9, pp. 1279-1281
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top